Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Investments (2016 - 2021)

Lifecore Biomedical, Inc. \De\ (LFCR) has 11 years of Long-Term Investments data on record, last reported at $44.8 million in Q2 2021.

  • For Q2 2021, Long-Term Investments fell 21.32% year-over-year to $44.8 million; the TTM value through May 2021 reached $44.8 million, down 21.32%, while the annual FY2021 figure was $44.8 million, 21.32% down from the prior year.
  • Long-Term Investments reached $44.8 million in Q2 2021 per LFCR's latest filing, down from $45.1 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $68.1 million in Q4 2018 and bottomed at $44.8 million in Q2 2021.
  • Average Long-Term Investments over 5 years is $59.7 million, with a median of $62.4 million recorded in 2017.
  • Peak YoY movement for Long-Term Investments: grew 4.94% in 2017, then fell 26.43% in 2020.
  • A 5-year view of Long-Term Investments shows it stood at $65.8 million in 2017, then grew by 3.5% to $68.1 million in 2018, then fell by 9.99% to $61.3 million in 2019, then dropped by 26.43% to $45.1 million in 2020, then fell by 0.73% to $44.8 million in 2021.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $44.8 million in Q2 2021, $45.1 million in Q1 2021, and $45.1 million in Q4 2020.